Carna Biosciences (TSE:4572) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Carna Biosciences's Liquidation Value for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carna Biosciences Total Current Assets Related Terms
Carna Biosciences Total Current Assets Historical Data
* Premium members only.
The historical data trend for Carna Biosciences's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of 円1,175.5 Mil mean?
Carna Biosciences (TSE:4572) has a Total Current Assets of 円1,175.5 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Carna Biosciences and its competitors.
Is Carna Biosciences' Total Current Assets too high?
Carna Biosciences' current Total Current Assets is 円1,175.5 Mil. Overall, Carna Biosciences has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Total Current Assets compare to VRTX and REGN?
Carna Biosciences' Total Current Assets of 円1,175.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Carna Biosciences and its competitors. Carna Biosciences's current Total Current Assets is 円1,175.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円188.38, compared to a current price of 円339.00 — trading 80% above its estimated fair value. The current Total Current Assets is 円1,175.5 Mil. Carna Biosciences' overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Total Current Assets is 円1,175.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carna Biosciences (TSE:4572) Overvalued in 2026?
Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued.
The current stock price of 円339.00 is trading 80% above its estimated GF Value™ of 円188.38.
GuruFocus considers Carna Biosciences to be Significantly Overvalued.
Key valuation signals for TSE:4572:
Total Current Assets: 円1,175.5 Mil
GF Value™: 円188.38 vs. price of 円339.00 (80% above fair value)
No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
34GF Score
Get the complete analysis for TSE:4572
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4572 has been successfully added to your 
